IRB review and human subjects protection in psychedelic research

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Researchers, sponsors, and institutions planning or conducting a psychedelic study involving human participants.

The short answer

Every study that exposes human participants to an investigational drug must be reviewed and approved by an institutional review board before it begins, and that approval must be maintained throughout the study. The board examines the protocol, the risks and anticipated benefits, and the informed-consent process to ensure that participants are protected. Psychedelic trials raise particular human-subjects concerns because of the intensity of the experience, the vulnerability of participants during dosing, and the potential for boundary violations or abuse in the context of extended therapeutic contact. A researcher cannot start enrolling participants because the science seems promising; the IRB review is a condition, not a formality.

What an IRB does and where the requirement comes from

An institutional review board is a committee that reviews research involving human subjects to protect their rights and welfare. The requirement comes from the federal Common Rule, a set of regulations that apply to research funded or conducted by federal agencies, and from FDA regulations that apply to research involving investigational drugs regardless of funding source. Together these cover most psychedelic clinical trials. The board reviews each study before it begins, reviews changes during the study, and monitors the research on an ongoing basis. An institution that conducts human-subjects research without IRB approval violates federal law and can lose the ability to receive federal funding.

What the IRB reviews

The board examines the protocol against a set of criteria the federal rules require it to apply. The risks to participants must be minimized and reasonable in relation to anticipated benefits and the importance of the knowledge to be gained. Participant selection must be equitable, avoiding overloading populations that are already vulnerable or underserved. Informed consent must be sought from each participant, documented in writing, and adequate in its disclosure of what the study involves. Where a study involves participants who are likely to be vulnerable, additional protections apply. A psychedelic trial implicates several of these criteria in ways that a standard drug trial may not.

Psychedelic-specific human-subjects concerns

Psychedelic trials require the IRB to examine questions that standard pharmacology protocols do not raise as directly. Participants spend hours in an altered state in the presence of study therapists or guides, which creates the conditions for boundary violations or abuse. The board must assess how the protocol structures and supervises that contact. The informed-consent process has to prepare participants for the nature and intensity of the experience, not only the clinical risks, and the participant’s capacity to consent at the time of dosing is relevant because the drug itself alters cognition and perception. Adverse psychological events, including the emergence of difficult memories and transient psychotic reactions, have to be anticipated in the protocol and addressed in the consent. IRB review and human subjects protection in psychedelic research — this article — and Informed consent beyond the OHA template: what additional provisions matter cover overlapping territory from different settings.

Consent in a clinical trial must meet the federal requirements for what participants are told, including the nature of the research, the reasonably foreseeable risks, the benefits, the alternatives, and the fact that participation is voluntary and can be withdrawn. In a psychedelic trial the consent also has to prepare participants for what the experience may actually be like, because a participant who does not understand what they are agreeing to may not be in a position to respond to it in a way that keeps them safe. The IRB reviews the consent document and the process by which it is obtained. A rushed or inadequate consent process is grounds for withholding approval.

Continuing review and adverse-event reporting

IRB oversight does not end when a study begins. The board conducts continuing review of ongoing research, and the sponsor must report unanticipated problems involving risks to participants or others, and serious adverse events, to the IRB as they occur. If the board finds that a study is no longer approvable, it can suspend or terminate it. The FDA also requires reporting of unexpected serious adverse reactions to the agency, covered in IND applications and FDA oversight of psychedelic clinical trials, and the IRB and FDA reporting obligations run in parallel.

Single-site vs. central IRBs

A study conducted at a single site uses that site’s IRB. A multi-site study can use each site’s local board or a single central IRB that reviews on behalf of all sites. The federal rules were amended in 2018 to require use of a single IRB for most multi-site federally funded research, to reduce the burden of redundant review. Central IRB review is common in larger psychedelic trials sponsored by biotech companies. Each site still carries its own institutional responsibilities even when it relies on a central IRB.

What happens when a protocol changes

The sponsor must submit changes to the approved protocol to the IRB for review before implementing them, except where a change is necessary to eliminate an immediate hazard to participants. The IRB reviews the change under the same criteria as the original protocol. Implementing changes without IRB approval is a violation, and it can affect the validity of the data and the regulatory record.

When public information may be enough

The federal regulations governing IRB review are public, and the federal Office for Human Research Protections publishes guidance that explains the requirements in detail. A researcher can read those sources to understand what the IRB will examine and what a consent document must cover. Professional resources on human-subjects protection in psychedelic research are also available. The specifics of how a board applies the criteria to a particular protocol are worked out in the review itself.

When you should speak with a lawyer or regulatory professional

Preparing a protocol and consent documents for IRB submission, especially in a field where the board may have limited prior experience with psychedelic trials, benefits from input that anticipates the questions the board is likely to raise. Researchers who have worked through IRB approval for psychedelic studies can share what has worked, and regulatory counsel can help structure the protocol and the consent disclosures. An institution setting up a psychedelic research program for the first time should also have guidance on the policies and procedures the federal rules require the institution itself to have in place.

You might also want to read

This article provides general legal information, not legal advice, and does not create an attorney-client relationship. Psychedelic law differs by state and changes over time. Consult a licensed attorney in your jurisdiction before acting on anything described here.